April 2026 Category 2 Update On April 15, 2026, the FDA confirmed removal of injectable GHK-Cu from Category 2 because the original nominations were withdrawn
GHK-Cu Topical Application Topical GHK-Cu provides a complementary approach to injectable protocols
These rapid gains highlight how starved immune cells are of glutathione for Type 2 Diabetes recovery
other licensed providers Treatment options: Range of medications, therapies, and protocols available Pricing transparency: Clear monthly costs with no hidden fees Patient experience: Onboarding ease, follow-up quality, and support responsiveness Clinical outcomes: Evidence-based protocols and meaningful patient results 1
If you stop the therapy, your body will gradually return to its previous baseline of natural growth hormone production
After a few sessions, you will notice: Improved and consistent energy throughout the day Better sleep patterns and quality of sleep Improvement in mood Visible skin improvement It is important to note that changes with peptide therapy are not dramatic and do not occur overnight
